| Toggle Summary
|
PRO-PHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH NEW PATENTS IN THE U.S. AND AUSTRALIA
Patents Cover Use of DAVANAT® with Chemotherapy to Increase Effectiveness and Reduce Side Effects of Cancer Treatments
|
View HTML
|
| Toggle Summary
|
THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS DISCOVER THAT DAVANAT® ENHANCES THE ABILITY OF ANTITUMOR T LYMPHOCYTES TO KILL TUMOR CELLS
Pro-Pharmaceuticals' DAVANAT® Targets Galectin Proteins Secreted by Cancer Cells and Eliminates The Cancer's Ability to Evade the Immune System
|
View HTML
|
| Toggle Summary
|
Pro-Pharmaceuticals Expands Patent Coverage to Japan
Patent Covers Use of DAVANAT® with Chemotherapy to Increase Effectiveness and Reduce Side Effects of Cancer Treatments
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS SELECTS SAFC® TO RAMP-UP THE MANUFACTURE OF DAVANAT® FOR ANTICIPATED USE IN CLINICAL TRIALS & SALES IN COLOMBIA
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS' PRESENTATION AT NOBLE FINANCIAL CAPITAL MARKETS' SEVENTH ANNUAL EQUITY CONFERENCE TO BE WEBCAST LIVE
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS
|
View HTML
|
| Toggle Summary
|
Pro-Pharmaceuticals to Hold Conference Call to Provide Update Following Company's Annual Meeting of Stockholders
|
View HTML
|
| Toggle Summary
|
Pro-Pharmaceuticals Changes Company Name to Galectin Therapeutics
New Name Highlights Company's Scientific Expertise in Galectins Applied to the Treatment of Serious Diseases Such as Fibrosis and Cancer
|
View HTML
|
| Toggle Summary
|
Stockholders Approve All Proposals at Galectin Therapeutics' Annual Stockholders Meeting
Judge Paul Pressler Elected to the Board of Directors
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces the Appointment of Kevin Freeman and John Mauldin to the Board of Directors
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Present Corporate Update at NIBA Conference
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Expands European Patent Coverage
Patent Covers Use of GM-CT-01 with Chemotherapy to Increase Effectiveness and Reduce Side Effects of Cancer Treatments
|
View HTML
|
| Toggle Summary
|
ADDING and REPLACING Galectin Therapeutics Announces New Stock Trading Symbol "GALT"
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease
|
View HTML
|
| Toggle Summary
|
10X Fund Issues Statement Regarding Investment in Galectin Therapeutics
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Reports Financial Results for Second Quarter 2011
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Present Corporate Update at the Rodman & Renshaw HealthcareConference
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Posts New Corporate Presentation Video to its Website
Highlights Leadership Position Developing Galectin-Inhibiting Therapeutics to Treat Fibrosis & Cancer
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Board Member John Mauldin Plans to Purchase Stock Under 10b5-1 Plan; Company Featured in his e-newsletter "Thoughts from the Frontline"
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Elects Dr. Marc Rubin to its Board of Directors
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis
-- Abstract Accepted for Presentation at the European Association for Study of the Liver Special Conference on Liver Transplantation --
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Reports Third Quarter and Nine Months 2011 Financial Results
|
View HTML
|
| Toggle Summary
|
Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma
Trial to Evaluate the Safety and Efficacy of Immunomodulatory Compound, GM-CT-01, with Peptide Vaccine
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Provides Corporate Update
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Present Corporate Update at BIO CEO & Investor Conference
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Inc. Appoints Thomas A. McGauley as Acting Chief Financial Officer and Extends Term of Employment of Maureen E. Foley as Chief Operating Officer
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1,159,445 Units, Listing on Nasdaq and Effectiveness of Reverse Stock Split
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Inc. Announces Exercise of Over-Allotment Option
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Inc. Announces Closing of Public Offering of 1,333,361 Units
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Reports Full Year and Fourth Quarter 2011 Financial Results
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Present Promising New Therapeutic Approach for Fatty Liver Disease at Digestive Disease Week 2012
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces Long-term Engagement of Dr. Scott Friedman to Advise on Liver Fibrosis Programs
-Renowned Physician and Researcher in Liver Diseases-
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Reports First Quarter 2012 Financial Results
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel Combination Therapy for Advanced Metastatic Melanoma
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Host Symposium on Galectin Science and Therapeutic Applications September 17-19, 2012
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces Addition to Russell Microcap Index
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Planning Clinical Trials for Early 2013 to Treat Fatty Liver Disease with Advanced Fibrosis After Recent FDA Meeting
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Reports Second Quarter 2012 Financial Results
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Present at the RedChip Small-Cap Equities Virtual Conference
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Appoints Harold H. Shlevin, PhD, Bioscience Industry Executive, as Chief Operating Officer
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces Relocation of Corporate Headquarters to Atlanta, GA
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Hosted International Conference on Galectins and Disease
--Proceedings from the Conference to be Published in Early 2013--
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Reports Third Quarter 2012 Financial Results
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis
|
View HTML
|
